Business Context and Reporting Period
This Form 8-K is filed by Atlantic Technology Ventures, Inc. (not TG Therapeutics, Inc., as indicated in the metadata) for the reporting period of January 25, 2001. The filing addresses "Other Events" regarding amendments to investment terms with BH Capital Investments, L.P. and Excalibur Limited Partnership (collectively, the "Investors") concerning Series B convertible preferred stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on contractual amendments regarding stock repurchase conditions.
Material Changes
On January 25, 2001, Atlantic and the Investors agreed to amend the Purchase Agreement regarding the definition of a "Repurchase Event":
- Definition Clarification: References to "the Company" in items (10) and (11) of the "Repurchase Event" definition were changed to specifically refer to Optex Ophthalmologics, Inc., Atlantic's majority-owned subsidiary.
- Waiver of Trigger: The Investors waived any Repurchase Event triggered by item (12), which concerns the failure of the average closing bid price of Atlantic's common stock to exceed $1.00 per share for the ten trading days preceding January 31, 2001.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of general business risks. The primary contingency addressed is the specific waiver of a stock price-based repurchase trigger, mitigating the immediate risk of a forced stock repurchase by the company due to the stock price falling below $1.00.
Investor Verification Checklist
- Verify the current status of the Series B convertible preferred stock and the outstanding warrants.
- Confirm the financial health and operational status of the subsidiary, Optex Ophthalmologics, Inc., given its specific inclusion in the repurchase definition.
- Review the historical stock price performance of Atlantic Technology Ventures, Inc. relative to the $1.00 threshold mentioned in the waived clause.
- Examine prior 8-K filings (Dec 11, Dec 29, Jan 24, 2001) referenced in the text to understand the full history of amendments to the Stock Purchase Agreement.